Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 8CNS 1Breast 1

Conditions

Triple Negative Breast Neoplasms 5Breast Neoplasms 5Neoplasm Metastasis 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Multiple Myeloma 2Melanoma 2Lymphoma, Non-Hodgkin 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2Leukemia, Myeloid, Acute 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hodgkin Disease 2Uveal Melanoma 1Thyroid Carcinoma, Anaplastic 1Thrombocytosis 1Testicular Neoplasms 1Teratoma, Testicular 1Teratoma 1Seminoma 1Sarcoma 1Prostatic Neoplasms 1Primary Myelofibrosis 1Pancreatic Neoplasms 1Osteosarcoma 1Neuroblastoma 1Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1

Interventions

Nivolumab 2Cyclophosphamide 2tislelizumab 1spartalizumab 1pembrolizumab 1montanide ISA 51 1glembatumumab vedotin 1fludarabine phosphate 1entinostat 1cemiplimab 1Toll-Like Receptor 1 1Surveys and Questionnaires 1Specimen Handling 1Rose Bengal 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Interleukin-2 1Interleukin-13 1Focus Groups 1Fluorodeoxyglucose F18 1Cryosurgery 1CTLA-4 Antigen 1CR011-vcMMAE 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Uveal Melanoma × CTLA-4 Antigen × Breast × Clear all
NCT03326258 2018-07-18

Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1/2 Withdrawn
BreastDermatologic

Uveal Melanoma, Breast Neoplasms, Melanoma, Neoplasm Metastasis, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡